Hypoxia and Medicine - Ischemia News

Ischemia News

ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology Tuesday, August 26, 2008 @ 2:59PMThe Medicines Company (NASDAQ: MDCO) announced that a sub-analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) study, published in the September 2, 2008 issue of the Journal of American College of Cardiology, shows that Angiomax(R) (bivalirudin) monotherapy provides moderate- and high-risk (unstable angina (UA)/non - ST elevation myocardial infarction) acute ...
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology Tuesday, August 26, 2008 @ 2:43PMThe Medicines Company (10523;NASDAQ:MDCO) announced that a sub-analysis of the ACUITY (Acute Catheterization
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology Tuesday, August 26, 2008 @ 2:30PM PARSIPPANY, N.J.----The Medicines Company announced that a sub-analysis of the ACUITY study, published in the September 2, 2008 issue of the Journal of American College of Cardiology, shows that Angiomax® monotherapy provides moderate- and high-risk (unstable angina /non - ST elevation myocardial infarction) acute coronary syndrome patients , who are undergoing percutaneous coronary ...
Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call Tuesday, August 26, 2008 @ 1:43PMAastrom Biosciences, Inc. (NASDAQ:ASTM) announces the following Webcast:
Webcast Alert: Aastrom Announces Fourth Quarter Investor Conference Call Tuesday, August 26, 2008 @ 1:29PMAastrom Biosciences, Inc. (816;NASDAQ:ASTM) announces the following Webcast: What: Aastrom Biosciences,
Study shows PDE5 inhibitor more effective when used on demand in erectile dysfunction Tuesday, August 26, 2008 @ 9:40AMNerve-sparing radical prostatectomy is the gold-standard therapy for prostate cancer in men with a life expectancy of 10 years or more.
PDE5 Inhibitor More Effective When Used On-demand In Erectile Dysfunction, Study Shows Tuesday, August 26, 2008 @ 8:14AMA new study shows for the first time that vardenafil, a PDE5 inhibitor, is more efficacious when used on-demand in men with erectile dysfunction, supporting a shift towards on-demand dosing with PDE5 inhibitors in this patient group.
Doppler effect Tuesday, August 26, 2008 @ 4:10AM Neurologists at Ingalls Memorial Hospital in Harvey are using a high-tech form of Doppler ultrasound to analyze blood flow in the brain and assess the risk of stroke. The procedure, known as transcranial Doppler ultrasonography, is a painless, noninvasive method of analyzing blood flow through the carotid arteries or the arteries at the base of the brain using high-frequency sound waves.
Bayer And Onyx Begin Enrollment In STORM Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer Friday, August 22, 2008 @ 7:14AMBayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced the companies have begun enrolling patients in the STORM Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma trial.
Scientific breakthrough! No embryonic stem cells needed Thursday, August 21, 2008 @ 11:25PMThe abortion-rights arguments that cite embryonic stem cells as the potential solution for a vast array of human diseases has taken another significant hit with an announcement from a San Francisco research and development company that it has defined and isolated an adult cell that has been shown to develop into tissues matching those in the heart, lung, liver, pancreas, blood vessels, brain, ...
Stem cell cos could be allowed to go for phase-III trials: Dr Ramananda Nadig Thursday, August 21, 2008 @ 9:44PMGoing by the advanced research activities of stem cell companies and increasing evidence of Mesenchymal stem cell efficacy and safety to treat many of the life threatening conditions like spinal cord injury, myocardial infarction and leg ischemia in India, the Union ministry of health could permit phase-III safety and efficacy trials for this therapy.
News From The Journal Of Neuroscience Thursday, August 21, 2008 @ 5:16AM1. Wnt Effects on Growth Cone Microtubules Silvia A. Purro, Lorenza Ciani, Monica Hoyos-Flight, Eleanna Stamatakou, Eliza Siomou, and Patricia C. Salinas Wnt family proteins are secreted from target tissues and regulate axonal terminal arborization during development.
Medistem Publishes Positive Preclinical Data On Menstrual Derived Stem Cells Wednesday, August 20, 2008 @ 7:15AMMedistem Laboratories (OTCBB: MEDS) reported positive efficacy data supporting development of its lead product, the Endometrial Regenerative Cell (ERC) for treatment of an advanced form of peripheral artery disease known as critical limb ischemia.
Policy for stem cells in cold storage, first draft made in 2006 Tuesday, August 19, 2008 @ 9:44PMThe Centre is yet to finalize the policy of stem cells even after a draft for the same was submitted early this year. The policy draft was made by Dr Vasantha Muthuswamy of Indian Council of Medical Research (ICMR) and a team of experts after several months of preparation.
Affitech signs antibody development agreement with Omeros Tuesday, August 19, 2008 @ 8:54PMAffitech and Omeros have signed an agreement for the discovery and development of fully human antibodies for Omeross MASP-2 program.
health scene Saturday, August 16, 2008 @ 9:19PMHealth Scene includes free and low-cost classes, screenings and events. Submit items by noon Tuesday for publication the following week. Include a daytime phone number readers may call.
Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles Friday, August 15, 2008 @ 11:11AMLAKE LAS VEGAS , Nev., BUSINESS WIRE -- The Noble Financial Capital Markets M.A.D. MAX Equity Conference takes place August 18, 2008 - August 19, 2008 at Loews Lake Las Vegas in Henderson.
Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles Friday, August 15, 2008 @ 10:30AMThe Noble Financial Capital Markets M.A.D. MAX Equity Conference takes place August 18, 2008 - August 19, 2008 at Loews Lake Las Vegas in Henderson. Listed below are the Noble Financial Capital Markets M.A.D. MAX Equity Conference presenter profiles. For in-depth information about the event, visit http://www.noblemadmax.com/madmaxhome.htm.
Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles Friday, August 15, 2008 @ 10:04AM LAKE LAS VEGAS, Nev.----The Noble Financial Capital Markets M.A.D. MAX Equity Conference takes place August 18, 2008 - August 19, 2008 at Loews Lake Las Vegas in Henderson. Listed below are the Noble Financial Capital Markets M.A.D.
Palatin Technologies, Inc. Reports Positive Results Of Phase 2a Clinical Study With PL-3994 For The Treatment Of Heart ... Friday, August 15, 2008 @ 6:15AMPalatin Technologies, Inc. (Amex: PTN) announced the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF).
REMINDER: ORLive Presents: Innovations in Stroke Prevention: An Update in Carotid Stenting Friday, August 15, 2008 @ 6:15AM Carotid stenting has been performed in the United States for over a decade and has been undergoing pivotal FDA device approval trials since 2000. Since 2004, 6 FDA-approved carotid stents have emerged for the subset of patients with severe carotid artery stenosis for whom endarterectomy, still the standard operation, carries a high surgical risk.
OrthoLogic Announces Completion of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring Thursday, August 14, 2008 @ 7:00PM TEMPE, Ariz., Aug. 14, 2008 -- OrthoLogic Corp. announced today the completion of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring. Patient follow-up is ongoing.
ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy Thursday, August 14, 2008 @ 10:46AM ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed William R.
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart ... Thursday, August 14, 2008 @ 6:30AM Palatin Technologies, Inc. announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist under development for treatment of heart failure .
Medistem Reports Second Quarter Financial Results Wednesday, August 13, 2008 @ 8:41PM Medistem Inc. today reported financial results for the quarter ended June 30, 2008.
Molecular Insight losses rise Wednesday, August 13, 2008 @ 10:42AMMolecular Insight Pharmaceuticals Inc. reported a big jump in net losses during its fiscal 2008 second quarter, driven in part by higher research and development costs and new clinical trials.
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results Wednesday, August 13, 2008 @ 7:54AMMolecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today financial results for the second quarter and six months ended June 30, 2008 and provided guidance for clinical milestones through the first half of 2009.
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis Of Viprinex(TM) Phase 3 Stroke ... Wednesday, August 13, 2008 @ 5:12AMNeurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of acute ischemic stroke has reached the level of patients necessary to conduct a planned interim analysis across the two studies.
Medistem Inc. Announces New Ticker Symbol Following Reverse Split and Name Change Tuesday, August 12, 2008 @ 2:28PM Medistem Inc. today announced a change in its corporate name and trading symbol.
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke ... Tuesday, August 12, 2008 @ 5:30AM Neurobiological Technologies, Inc. today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex for the treatment of acute ischemic stroke has reached the level of patients necessary to conduct a planned interim analysis across the two studies.
K-115, an ophthalmic solution for the treatment of glaucoma Monday, August 11, 2008 @ 4:17PMK-115 is a small molecule, new chemical compound that selectively inhibits Rho kinase. Kowa is developing K-115 in Japan as an ophthalmic solution for the treatment of glaucoma.
Cardium Reports on Second Quarter 2008 Highlights and Financial Results Monday, August 11, 2008 @ 8:00AM Cardium Therapeutics today reported recent highlights and developments, as well as financial results for its second quarter ended June 30, 2008.
OrthoLogic Announces Chrysalin (TP508) Demonstrates Significant Benefit in a Pre-Clinical Model of Acute Heart Disease Thursday, August 7, 2008 @ 8:00AM TEMPE, Ariz., Aug. 7, 2008 -- OrthoLogic Corp. announced today that Chrysalin , administered following the onset of ischemia, has shown a statistically significant benefit in a recently completed pre-clinical study designed to assess cardioprotective effects in a model of acute myocardial infarction .
Exercise Pill Is No Replacement For Exercise Wednesday, August 6, 2008 @ 5:19AMRecently, researchers at the Salk Institute for Biological Studies, a research organization focused on biology and its relation to health, published a study in the journal Cell on the results of a substance that increased exercise endurance without daily exertion when tested in mice. Media reports have described this substance as an "exercise pill," potentially eliminating the need for exercise.
Vical Reports Second Quarter and First Six Months 2008 Financial Results and Highlights in Product Development Programs Tuesday, August 5, 2008 @ 5:30AM Vical Incorporated today reported financial results for the quarter and six months ended June 30, 2008. Revenues for the second quarter of 2008 were $2.5 million, compared with revenues of $3.1 million for the second quarter of 2007.
Family of Ereck Plancher to file wrongful death suit against UCF Saturday, August 2, 2008 @ 4:51PMThe parents of a onetime Lely High School football star who died after a practice at the University of Central Florida say they intend to file a wrongful death suit against the university. Ereck Plancher, a 19-year-old redshirt freshman, collapsed during an offseason conditioning workout on March 18 in Orlando during UCF’s spring drills and later died. The attorney for the family, J.D. Dowell, ...
Palmerton doctor certified in vascular neurology Friday, August 1, 2008 @ 4:24PM
Pill turns wimps into mighty mice Friday, August 1, 2008 @ 8:40AMScientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill.
Drug test on mice reveals taking a pill could burn fat without exercise Friday, August 1, 2008 @ 7:35AMa change in makeup of muscle Scientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill.
Drug builds mighty mouse Friday, August 1, 2008 @ 3:47AMChemical compound burns fat, builds muscle without physical activity Scientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill. In experiments on mice that did no exercise, the chemical compound, known as AICAR, allowed them to run 44 percent farther on a treadmill than those that did not receive the drug.The drug, according to the researchers, ...
Take a pill, burn off fat? Friday, August 1, 2008 @ 2:51AMDrug test on mice reveals a change in makeup of muscle Scientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill.
What if fat-burning workout consisted of popping a pill? Friday, August 1, 2008 @ 2:28AMScientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill. Researchers at the Salk Institute...
Drug may be exercise in a pill, scientists say Friday, August 1, 2008 @ 12:21AMBy ALAN ZAREMBO Scientists have discovered what could be the ultimate workout for couch potatoes: exercise in a pill. In experiments on mice that did no exercise, the chemical compound known as AICAR allowed them to run 44 percent farther on a treadmill than those that did not receive the drug. The drug, according to the researchers, changed the physical composition of muscle, essentially ...
Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference Thursday, July 31, 2008 @ 10:30AM ANN ARBOR, Mich., July 31, 2008 -- Aastrom Biosciences, Inc. ), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2008 BMO Capital Markets Focus on Healthcare Conference.
New Treatment Lessens Heart Attack Damage Wednesday, July 30, 2008 @ 5:20PMTransplant drug cyclosporine limits injury from blood rushing back to heart, researchers say.
New Treatment Lessens Heart Attack Damage Wednesday, July 30, 2008 @ 4:49PM By Ed Edelson , HealthDay Reporter WEDNESDAY, July 30 (HealthDay News) -- Giving the transplant drug cyclosporine to heart attack patients can prevent the injury...
Dutton Associates Announces Investment Opinion: Pluristem Therapeutics Speculative Buy Rating Maintained In Update ... Wednesday, July 30, 2008 @ 9:50AMDutton Associates continues coverage of Pluristem Therapeutics (Nasdaq:PTSI) reiterating its Speculative Buy rating and a 12-month $6.50 price target. The 10-page report by Dutton senior analyst Denise T. Resnik, MS is available at www.duttonassociates.com, and at First Call, Bloomberg, Capital IQ, FactSet, Reuters, Zacks, Knobias, and other leading financial portals.
Dutton Associates Announces Investment Opinion: Pluristem Therapeutics Speculative Buy Rating Maintained In Update ... Wednesday, July 30, 2008 @ 9:27AM ROSEVILLE, Calif.----Dutton Associates continues coverage of Pluristem Therapeutics reiterating its Speculative Buy rating and a 12-month $6.50 price target. The 10-page report by Dutton senior analyst Denise T.
Molecular Insight Pharmaceuticals, Inc. To Announce Second Quarter Financial Results on August 13, 2008 Wednesday, July 30, 2008 @ 7:30AM CAMBRIDGE, Mass.----Molecular Insight Pharmaceuticals, Inc. announced today that it will release its second quarter 2008 financial results before the opening of the stock market and will hold a conference call on Wednesday, August 13, 2008 at 10:00 AM Eastern Time.
Exercise rejuvenates heart muscle Tuesday, July 29, 2008 @ 6:13AMAbsence may make the heart grow fonder, but exercise may do something even better: It seems to make the heart younger.